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The humoral response to Plasmodium falciparum
VarO rosetting variant and its association with
protection against malaria in Beninese children
Inès Vigan-Womas1,2†, Adjimon Lokossou3,4,5,6†, Micheline Guillotte1,2, Alexandre Juillerat7,8, Graham Bentley7,8,
André Garcia3,4,5,6, Odile Mercereau-Puijalon1,2, Florence Migot-Nabias3,4,5,6*
Abstract
Background: The capacity of Plasmodium falciparum-infected erythrocytes to bind uninfected erythrocytes
(rosetting) is associated with severe malaria in African children. Rosetting is mediated by a subset of the variant
surface antigens PfEMP1 targeted by protective antibody responses. Analysis of the response to rosette-forming
parasites and their PfEMP1 adhesive domains is essential for understanding the acquisition of protection against
severe malaria. To this end, the antibody response to a rosetting variant was analysed in children recruited with
severe or uncomplicated malaria or asymptomatic P. falciparum infection.
Methods: Serum was collected from Beninese children with severe malaria, uncomplicated malaria or P. falciparum
asymptomatic infection (N = 65, 37 and 52, respectively) and from immune adults (N = 30) living in the area.
Infected erythrocyte surface-reactive IgG, rosette disrupting antibodies and IgG to the parasite crude extract were
analysed using the single variant Palo Alto VarO-infected line. IgG, IgG1 and IgG3 to PfEMP1-varO-derived NTS-
DBL1a1, CIDRg and DBL2bC2 recombinant domains were analysed by ELISA. Antibody responses were compared in
the clinical groups. Stability of the response was studied using a blood sampling collected 14 months later from
asymptomatic children.
Results: Seroprevalence of erythrocyte surface-reactive IgG was high in adults (100%) and asymptomatic children
(92.3%) but low in children with severe or uncomplicated malaria (26.1% and 37.8%, respectively). The IgG, IgG1
and IgG3 antibody responses to the varO-derived PfEMP1 domains were significantly higher in asymptomatic
children than in children with clinical malaria in a multivariate analysis correcting for age and parasite density at
enrolment. They were essentially stable, although levels tended to decrease with time. VarO-surface reactivity
correlated positively with IgG reactivity to the rosetting domain varO-NTS-DBL1a1. None of the children sera,
including those with surface-reactive antibodies possessed anti-VarO-rosetting activity, and few adults had
rosette-disrupting antibodies.
Conclusions: Children with severe and uncomplicated malaria had similar responses. The higher prevalence and
level of VarO-reactive antibodies in asymptomatic children compared to children with malaria is consistent with a
protective role for anti-VarO antibodies against clinical falciparum malaria. The mechanism of such protection
seems independent of rosette-disruption, suggesting that the cytophilic properties of antibodies come into play.
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Background
Despite recent scaling-up of control measures, Plasmo-
dium falciparum malaria still claims about one million
deaths each year, mainly young African children [1,2]. A
hallmark of P. falciparum infection is the sequestration
of infected erythrocytes (IE) in the microvasculature of
vital organs [3-8] resulting from cytoadherence of
mature IE to the endothelial cell lining and/or to other
circulating cells or uninfected erythrocytes (rosetting)
[9,10]. The P. falciparum Erythrocyte Membrane Protein
1 (PfEMP1), a variant adhesin displayed to the surface of
the IE and encoded by the var gene family, plays a
major role in IE cytoadherence [11-13].
There is a large body of evidence indicating that var-
iant antigens dominate the response to the IE surface in
children en route to acquiring protective immunity and
that PfEMP1 molecules are major targets of the variant-
specific responses [14-21]. The surface-exposed region
of PfEMP1 has a modular structure with a succession of
adhesion domains of two major types, namely the Duffy
Binding-Like (DBL) domain and the cysteine-rich Inter-
Domain Region (CIDR). Specific sequence signatures
allow the classification of these adhesive domains in dif-
ferent classes (classes a, a1, b, g, δ, ε, X for DBL; classes
a, a1, b and g for CIDR) [22]. Studies in endemic areas
have shown that multiple DBL and CIDR domains elicit
antibodies [19,23-25], but their association with protec-
tion remains unclear.
The rosetting and auto-agglutination cytoadherence
phenotypes are consistently associated with severe
malaria in African children [26,27]. Emerging evidence
indicates that rosetting is mediated by proteins encoded
by a subset of var genes, the exact number of which is
still unknown. Three rosetting lines have been character-
ized, expressing respectively the FCR3S1.2/IT4var21
[28,29], the R29/IT4var9 [30] and the Palo Alto varO
genes [31]. In all three lines the N-terminal DBL1a/a1
was identified as the binding domain for uninfected ery-
throcytes [28,30,31]. Little is known on the acquisition of
antibodies to rosette-forming parasite types. In a pioneer-
ing study, Carlson et al reported that only 8% of children
with cerebral malaria had antibodies disrupting the R
+PAl rosettes (subsequently called FCR3S1.2) [28], com-
pared to 38% in age-matched children with mild malaria
[32], suggesting that rosette-disrupting antibodies contri-
bute to protection against severe malaria. Whether anti-
bodies to other rosetting types contribute to protection
as well is unknown. It is not known either whether the
antibody isotype, in particular cytophilic antibodies tar-
geting the IE surface and promoting its opsonization also
come into play to protect children against clinical malaria
as observed in the Saimiri sciureus monkey [33,34].
Furthermore, how rosette-disrupting antibodies relate to
IE-surface reacting antibodies and to their specificity with
regard to the individual PfEMP1 domains exposed on the
IE surface remains unclear.
Experimental obstacles to such studies have been the
non-homogeneity of IE surface-displayed PfEMP1 mole-
cules in cultivated lines (a consequence of antigenic var-
iation) and the difficulty in producing appropriately
folded recombinant PfEMP1 domains. A recombinant
varO-NTS-DBL1a1 domain was produced in the native
conformation that induced high titres of IE surface-
reacting antibodies and rosette-disrupting antibodies
[31,35]. Panning using a monoclonal antibody (mAb)
raised to the recombinant domain allowed a “single var-
iant” VarO culture to be established, in which all IE
express the single VarO serotype [31]. A study in Sene-
gal with this single variant culture showed that the sero-
prevalence of VarO was very high and strongly age-
dependent, with high levels of VarO-IE surface-reactive
and NTS-DBL1a1-reactive antibodies being reached at
an age when effective protection against clinical malaria
is established [31].
The present study was aimed at investigating seropre-
valence to VarO-IE surface and to varO-PfEMP1 recom-
binant domains in a second, geographically distant
endemic area exposed to different transmission condi-
tions and at analysing its possible association with pro-
tection against severe and/or uncomplicated clinical
malaria. The antibody response to the VarO serotype
was investigated in Benin among immune adults, semi-
immune children with P. falciparum asymptomatic para-
sitaemia and children with mild or severe P. falciparum
malaria disease. The varO-IE surface seroreactivity and
VarO rosette disrupting capacity were analysed. Total
IgG, IgG1 and IgG3 responses to three PfEMP1-varO
recombinant domains (NTS-DBL1a1, CIDR1g and
DBL2bC2), which could be produced as soluble, prop-
erly folded recombinant proteins capable of inducing
high titres of VarO surface-reacting antibodies in the
mouse, were assessed. Data indicate an elevated seropre-
valence to varO-IE surface and recombinant domains in
asymptomatic children and immune adults, contrasting
with a low prevalence and low antibody levels in chil-
dren with clinical malaria. Intriguingly rosette-disrupting
antibodies were rare in immune adults and not detect-
able in all children including in asymptomatic children,
suggesting that mechanisms other than prevention of
rosetting may operate to protect against VarO parasites.
Methods
Study areas and sample collection
Clinical and parasitological characteristics of the
recruited subjects are presented in Table 1. From July
2006 to January 2007, 102 children with symptomatic
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P. falciparum malaria were recruited in three health
centres (Saint-Luc, Béthesda and Cotonou hospitals)
located in the urban area of Cotonou where malaria
transmission is perennial, with two seasonal peaks corre-
sponding to rainy seasons, from April to July and Sep-
tember to November. A survey conducted in 2000
showed heterogeneous malaria transmission in the city
of Cotonou, with transmission varying from 5, 29 and
47 infective bites per person per year near the beach, in
the centre of the city and in the outer-urban lagoon
areas, respectively [36]. The inoculation rates were
undoubtedly lower during the study period, due to the
introduction of effective prevention and therapy.
According to clinical and parasitological features at
admission described elsewhere [37], children were
assigned to the severe malaria (SM, n = 65) or uncom-
plicated malaria (UM, n = 37) group. SM was defined as
the association of fever (axillary temperature ≥ 37.5°C),
presence of circulating P. falciparum ring forms and a
neurologic Blantyre score < 3. Forty-two SM children
presented cerebral malaria (coma duration ≥ 6 h) and
eight had severe malarial anaemia (haemoglobin level
< 5 g/dL). The fifteen remaining SM children combined
a Blantyre coma score < 3, coma duration < 6 h as well
as haemoglobin level ≥ 5 g/dL but clinical signs of anae-
mia. For the UM group, inclusion criteria were fever or
history of fever during the last 24 hours, the presence of
circulating P. falciparum ring forms and a Blantyre
coma score ≥ 3. Blood was withdrawn before the admin-
istration of any drug. An anti-malarial treatment was
administered in accordance with the treatment practices
of each hospital.
In December 2006, 52 children with asymptomatic fal-
ciparum parasitaemia (AP) were enrolled in the primary
schools of Ouidah, a semi-rural town situated 35 km
west from Cotonou. The entomological inoculation rate
averaged 2.05 ± 1.28 infective bites per human per 100
nights in the nearby rural area of Tori Bossito [38]. AP
children were non-febrile at enrolment or during the
preceding 24 hours, but presented circulating P. falci-
parum ring forms. In two out of 52 cases, the appear-
ance of fever in a delay of 3 days after enrolment led to
the administration of antipyretics associated with an
artemisinin-based combination therapy (ACT), as
recommended by the National Malaria Control Pro-
gramme. Another blood sample was collected from the
same children one year later (January 2008).
Plasma samples from 30 healthy adults (HA) living in
the rural area of Tori-Bossito, which is located halfway
of Cotonou and Ouidah were used as controls of the
acquired anti-malarial immunity in this area. These
adults were bled in November 2008.
For each individual, a venous blood sample was col-
lected in EDTA Vacutainer tubes. Plasmas were col-
lected and stored at -20°C for subsequent antibody
testing. Blood smears were prepared to determine
blood-stage infection and parasitaemia by microscopy.
Negative control plasmas were obtained from 20 healthy
Europeans adults who had not been exposed to malaria
(Blood bank, EFS-Rungis, France) and were used either
individually or grouped into a negative control pool
(NC). For a positive control (PC), a pool of plasma
taken from adult donors living in Dielmo, Senegal, was
used, that showed high antibody reactivity to the surface
of VarO-IE [31].
This study has been approved by the ethic committee
of “Faculté des Sciences de la Santé” of the University of
Abomey-Calavi in Benin. For each child, a written
informed consent from parents or legal guardians was
obtained. The study was conducted in accordance with
the Declaration of Helsinki.
Surface immunofluorescence assay (S-IFA) and rosette
disruption
Single variant Palo Alto 89F5 VarO parasites were culti-
vated in human O+ RBC. Weekly enrichment of rosettes,
monthly positive selection by panning on a mouse mono-
clonal antibody raised to the varO-NTS-DBL1a1 domain
were done as described [31]. For surface immunofluores-
cence assay, an aliquot of rosette-enriched 89F5 VarO
parasites was incubated with the plasma sample (final dilu-
tion 1:20). Total IgG binding was detected as described
[31]. Surface reactivity was expressed in arbitrary units
(AU) as follows: [(% IE+sample - % IE
+
NC)/(% IE
+
PC - %
Table 1 Clinical and parasitological characteristics of the children at enrolment (year 2006): P. falciparum
asymptomatic children (AP), children with uncomplicated malaria (UM) and children with severe malaria (SM)
Parameters AP (n = 52) UM (n = 37) SM (n = 65) P
Sex ratio (M/F) 0.9 (24/28) 1.8 (24/13) 0.8 (29/36) 0.11 b
Age (yrs)
mean ± SD
6.5 ± 1.3 4.7 ± 3.4 2.9 ± 1.8 AP > UM > SM
(P < 0.0001) c
Parasite density
(/μl) a
811
(369-1,751)
24,900
(3,606-65,440)
61,920
(1,684-192,000)
AP < UM/SM
(P < 0.001) d
a Median parasite density (interquartile range IQ25-75).
b P value of the cχ2 test.
c P value of the Student’s unpaired-t-test.
d P value of the Mann-Whitney U-test.
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IE+NC)] × 100. The mean surface reactivity plus 3 standard
deviations observed with plasma samples from 20 non-
immune malaria individuals was used to set the positivity
threshold (20 AU).
For the rosette disruption assay, an aliquot of VarO
rosette-enriched parasites (20 μL, 5% parasitaemia,
> 85% rosetting frequency, in complete RPMI culture
medium) was incubated with plasma (final dilution 1/5)
for 30 min at 37°C as described [31]. Each plasma sam-
ple was assayed in duplicate. The rosetting rate was
compared to a control culture in complete RPMI med-
ium in presence of the NC pool. The positive control
was PC, a pool of hyper-immune sera of adults from
Dielmo (Senegal) and able to disrupt VarO rosettes [31].
Recombinant PfEMP1-varO domains
The soluble recombinant NTS-DBL1a1 domain (resi-
dues 1-487 of the predicted varO amino-acid sequence,
GenBank accession number EU908205) was produced in
insect cells [31]. Construction of the recodoned recom-
binant varO-CIDRg (residues 508 to 787) and varO-
DBL2bC2 (residues 831 to 1241) domains and produc-
tion of recombinant proteins will be described in detail
elsewhere (Guillotte et al, in preparation). Briefly, both
domains were produced from a recodoned coding
sequence where all potential N-glycosylation sites were
mutated. VarO-DBL2bC2 was produced in the baculo-
virus/insect cells system whereas varO-CIDRg was pro-
duced in Pichia pastoris. Each domain was produced as
a soluble protein with a C-terminal hexa-histidine-tag.
Protein purity was evaluated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
Western blot. The protein sequence was verified by N-
terminal sequencing and mass spectrometry analysis.
Alike the NTS-DBL1a1 domain [31,35] the recombinant
varO-CIDRg and varO-DBL2bC2 induced varO-IE sur-
face reactive antibodies in the mouse (Guillotte et al, in
preparation). The other varO-derived DBL domains
(DBL3, 4 and 5) were not available as recombinant pro-
teins with native folding and were not used in this
study.
Enzyme-linked immunosorbent assay (ELISA)
A crude extract of VarO-IE was prepared as described
[39]. IgG levels were quantified in plasma diluted 1/100
essentially by ELISA as described [31] using i) 100 μL of
the varO-IE crude extract or ii) 0.2 μg of recombinant
protein. For total immunoglobulin-G (IgG) detection,
plates were probed with an horseradish peroxidase
(HRP)-conjugate goat anti-human IgG-F(ab’)2 (Cappel,
France; dilution 1/7,500) [31]. For IgG-subclass (IgG1
and IgG3) analysis, plates were first incubated with a
mouse anti-IgG1 (clone NL16; dilution 1/2,000; Skybio,
England) or anti-IgG3 (clone ZG4; dilution 1/10,000;
Skybio, England) and probed with an HRP-conjugate
goat anti-mouse IgG (Promega, France; dilution 1/
3,000). Each serum was tested in duplicate. Negative
(NC) and positive (PC) controls were included in each
plate. Results were expressed in arbitrary units (AU) cal-
culated with the formula: 100 × [ln(OD tested plasma) - ln
(OD NC)]/[ln(OD PC) - ln(OD NC)] [40]. The threshold
for positivity was determined for each antigen and each
class/subclass from the 95th percentile of the antibody
reactivity of 20 individual plasma samples from non-
immune malaria individuals. For varO-NTS-DBL1a1 it
was 43.2, 14.0 and 17.3 AU for total IgG, IgG1 and
IgG3 respectively; for varO-CIDRg it was 30.6, 47.1 and
40.5 for total IgG, IgG1 and IgG3, respectively and for
varO-DBL2bC2 it was 32.4, 70.3 and 39.6 for total IgG,
IgG1 and IgG3, respectively. The positivity threshold
was set at 9.0 AU for total IgG to VarO-IE crude
extract.
Statistical analysis
Differences in proportions were analysed using the c2
test. Differences in means were tested by the non-para-
metric Mann-Whitney U-test, except for age, where the
Student’s unpaired t-test was employed as age was nor-
mally distributed. Statview 5.0 (SAS Institute Inc., Cary,
NC) was used for these calculations. The associations
between antibody responses and covariates (sex, age, P.
falciparum carriage at blood drawing) found to be sig-
nificant in the univariate analysis were investigated by
multiple linear regression analysis using STATA (Stata-
Corp. Release 8.0). The antibody levels in 2006 and
2008 for children sampled at these 2 time-points (n =
45) were compared using a non-parametric Mann-Whit-
ney U-test. In case of P value less than 0.20 in the uni-
variate analysis, a multiple linear regression was
performed including age as covariate, to take into
account the effect of aging on the evolution of antibody
levels. For all tests, P values of less than 0.05 were con-
sidered significant.
Results
Characteristics of the subjects recruited
Table 1 summarizes the main characteristics of the
three groups of children recruited for this study. P. falci-
parum asymptomatic children (AP, n = 52) were older
than children with uncomplicated malaria (UM, n = 37)
and children with severe malaria (SM, n = 65) (Student’s
t-test, P < 0.0001, for comparison between the groups).
Asymptomatic children presented a lower median para-
site density than children with uncomplicated or severe
malaria (P < 0.001). There was no difference regarding
gender, age and parasite density between SM clinical
sub-groups. The control group of immune adults (HA,
n = 30) comprised 15 men and 15 women, older than
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20 years, who were healthy at the time of blood
drawing.
VarO-IE surface-reactive antibodies: seroprevalence and
levels
Antibodies (total IgG) reacting with the VarO-IE surface
were studied using a single-variant parasite culture with
more than 95% IE at mature stages expressing the
PfEMP1-varO adhesin. All healthy, immune adults
reacted against the VarO-IE surface. Seroprevalence rate
was higher in AP children (92.3%, 95% confidence inter-
val [CI], 85.1 to 99.6) than in UM and SM children
(37.8% [95% CI, 22.2 to 53.5] and 26.2% [95% CI, 15.5
to 37.8], respectively) (Figure 1A). This difference
between AP children and children with clinical malaria
was highly significant (c2 test, P < 0001), but there was
no statistical difference between UM and SM children
as well as between UM and the CM sub-group of SM
children.
The level of VarO-IE surface reactive antibodies dif-
fered in the three groups of children, from nil or very
low in SM (median 11.21 AU, interquartile range IQ25-
75 = 7.57 - 20.25 AU), to low in UM children (median
16.71 AU, IQ25-75 = 10.85 - 33.67 AU) and high in AP
children (median 61.35, IQ25-75 = 35.19 - 97.5 AU).
The highest levels were observed for HA adults (median
97.71, IQ25-75 = 57.54 - 101.76 AU) (Figure 1B). The
surface-reactive antibody levels did not differ between
UM and SM (whole group but also CM sub-group), but
differed significantly between children with clinical
malaria and AP children. Multivariate analysis con-
ducted for children only confirmed the clinical malaria-
dependence of the level of VarO-surface reactive antibo-
dies (-17.07, P < 0.0001) in spite of a small positive
effect of age on antibody levels (1.91, P = 0.052), the
parasite density being without effect on these observa-
tions (P = 0.12).
The VarO-rosette dissociation assay showed that few
HA sera displayed anti-varO rosetting activity. Only 2 of
30 sera disrupted > 50% of the VarO rosettes of the cul-
ture, and 6 disrupted 10-50% of the rosettes. Most sera
had marginal to nil rosette disrupting activity, contrast-
ing with sera from Senegalese adults (Figure 2). None of
the children sera harbouring surface-reactive antibodies
(be they from asymptomatic or symptomatic children)
had detectable antibodies able to disrupt VarO rosettes.
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Figure 1 Surface-reactive antibodies to single-variant culture of VarO-IE. Plasma samples were obtained from healthy adults (HA, n = 30)
and children with asymptomatic P. falciparum infection (AP, n = 52), uncomplicated (UM, n = 37) or severe (SM, n = 65) malaria. For each child,
antibodies (total IgG) reacting with the surface of live VarO-IE were analyzed by S-IFA and flow cytometry. Results are expressed in arbitrary units
(AU, see Materials and Methods). (A) Prevalence (95% CI) of surface-reactive antibodies to VarO parasites in the four groups of individuals: HA, AP,
UM or SM. (B) Surface reactivity levels in HA, AP, UM or SM children. Box-whisker plots illustrate medians with 25th and 75th percentiles, and
whiskers for 10th and 90th percentiles. The outlying dots indicate values exceeding the 90th and 10th percentiles. The P values were estimated
using the c2 test (A) and the nonparametric Man-Whitney U-test (B). ***, P < 0.0001.
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Seroprevalence to VarO-IE crude extract and varO
recombinant domains
Total IgG, IgG1 and IgG3 responses to the individual varO
recombinant domains were analysed by ELISA. The sand-
wich ELISAs for IgG1 and IgG3 detected specific
responses in some children scored as negative for total
IgG reactivity, likely reflecting their higher sensitivity. To
rule out a technical issue with the quality of the sera, total
IgG reactivity with the VarO-IE crude extract was
determined.
In none of the assays did UM and SM children, as
well as UM and CM children, display a statistically
different response (Figure 3). Total IgG seroprevalence
to the recombinant antigens and the crude extract was
similarly high in HA adults and AP children. Seropre-
valence to the crude extract was lower in UM chil-
dren. Total IgG and IgG1 seroprevalence to the three
recombinant domains was higher in AP children than
in UM and/or SM children. Similar results were
observed for IgG3 except for seroprevalence to
NTS-DBL1a1 which was higher in AP children than
UM children but not different from SM children
(Figure 3).
NTS-DBL1a1 was the most frequently recognized
domain. For total IgG, the prevalence rates among chil-
dren were NTS-DBL1a1 > DBL2bC2 > CIDRg (paired
comparisons analysed by c2, all significant: odds-ratio
(OR) NTS-DBL1a1/DBL2bC2 = 7.7 [95% CI, 3.5 to
17.1]; NTS-DBL1a1/CIDRg = 19.5 [95% CI, 4.5 to 84.7];
DBL2bC2/CIDRg = 8.9 [95% CI, 3.7 to 21.2]; P < 0.0001
for each). Similar results were obtained for IgG1 and
IgG3 seroprevalence rates.
When examining the number of individual varO-
derived recombinant domains recognized in each group,
it was clear that HA adults had a broad reactivity, with
most sera (70%) reacting with each of the three domains
(Figure 4). The response in AP children was narrower,
as about 50% and 30% had antibodies reacting with
three or two domains, respectively. In contrast, the IgG
response of children with clinical malaria (UM or SM)
was quite restricted, with 49% and 42% respectively with
no detected seroreactivity to any of the three antigens
(Figure 4). The more sensitive IgG1 and IgG3 assays
reduced the percentage of seronegative children in each
clinical group, but still outlined a more restricted
response of the UM and SM children compared to AP
children (for each Ig assay, P < 0.0001 for AP vs. UM
and AP vs. SM when comparing reactivity to 0-1 and 2-
3 domains).
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Antibody levels to VarO-IE crude extract and varO
recombinant domains
HA adults and AP children presented similar total IgG
levels, except for VarO-IE crude extract (P = 0.0004)
(Table 2). NTS-DBL1a1 was the only recombinant
domain to generate lower total IgG, IgG1 and IgG3
levels in UM than in AP children (P = 0.02, P < 0.0001
and P < 0.0001, respectively). SM children had lower
total IgG, IgG1 and IgG3 levels to NTS-DBL1a1 than
AP children (P = 0.002, P < 0.0001 and P = 0.01, respec-
tively), as well as lower total IgG and IgG1 to CIDRg (P
= 0.04 and P = 0.007, respectively). The antibody levels
did not significantly differ in children with UM and SM,
except total IgG to VarO-IE crude extract (P = 0.03)
and IgG3 to NTS-DBL1a1 (P = 0.007) (Table 2). Similar
differences were observed when considering the CM
sub-group of SM children, except for CIDRg which eli-
cited comparable antibody levels among HA, AP, UM
and CM groups.
Importantly, age and parasite density were not asso-
ciated with any of the antibody level assayed in each of
the three groups of children, although this should be
qualified because of the limited number of responders.
A multivariate analysis taking into account sex, age and
parasite density confirmed higher levels of total IgG and
IgG subclasses in AP compared to symptomatic children
(all antigens P < 0.02, except for total IgG to NTS-
DBL1a1 [P = 0.05] and to DBL2bC2 [P = 0.06]). The
observed differences did not correlate with sex and
parasite density, and in some cases, the presence of an
age-related increase in antibody (IgG to NTS-DBL1a1
[P = 0.001] and to DBL2bC2 [P < 0.0001] as well as
IgG1 to DBL2bC2 [P < 0.0001]) did not counterbalance
the strong impact of the clinical presentation.
In each clinical group, the total IgG and IgG1 levels
reactive to an individual antigen were positively corre-
lated (Table 3). Total IgG and IgG1 were moderately
related to the IgG3 levels for NTS-DBL1a1 (Rho from
0.39 to 0.59, all P < 0.02) and for CIDRg (Rho from 0.38
to 0.49, all P < 0.003), and somewhat stronger with
DBL2bC2 (Rho from 0.42 to 0.72, all P < 0.002) (Table
3). Results were the same when considering the CM
sub-group, except for total IgG levels directed to CIDRg
which were not related to IgG1 and IgG3 levels (Rho =
0.20 and 0.26; P = 0.20 and 0.10, respectively).
Positive correlations between domain-reactive antibo-
dies were observed in the AP group for total IgG (NTS-
DBL1a1 vs. CIDRg: Rho = 0.63, P < 0.0001; NTS-
DBL1a1 vs. DBL2bC2: Rho = 0.49, P = 0.0002 and
CIDRg vs. DBL2bC2: Rho = 0.53, P < 0.0001) and IgG1
(NTS-DBL1a1 vs. CIDRg: Rho = 0.40, P = 0.004; NTS-
DBL1a1 vs. DBL2bC2: Rho = 0.46, P = 0.0006 and
0
10
20
30
40
50
60
70
HA AP UM SM AP UM SM AP UM SM
Pe
rc
e
n
t s
er
a
 
(%
)
IgG 3GgI1GgI
Figure 4 Frequency distribution of the reactivity to one or more PfEMP1-varO domain as by groups of healthy adults (HA) and
children recruited in 2006 (AP, UM or SM as indicated) and by Ig assay as indicated (total IgG for HA; total IgG, IgG1 and IgG3 for
AP, UM and SM). Reactivity was assessed by ELISA on individual domain as indicated in the Methods section. A plasma sample was classified as
seropositive when the recorded signal was above the threshold. Seroreactivity to 1, 2 or 3 domains is indicated irrespective of the actual domain
recognized in each class. Symbols used for bars: no domain recognized (white), any one domain recognized (grey), two domains recognized
(hatched), all three domains recognized (black).
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CIDRg vs. DBL2bC2: Rho = 0.40, P = 0.003). In the UM
and SM groups, a strong correlation was observed
between total IgG levels to NTS-DBL1a1 and DBL2bC2
(Rho = 0.74 and 0.52, P < 0.0001, respectively) but not
between the other domains, whether for total IgG or for
IgG1 and IgG3. The same profile of relationships was
confirmed for the CM sub-group of SM children.
Relationships between surface-reactive, varO-IE extract-
reactive and recombinant domain-reactive antibodies
For all four groups, the strongest correlations involving
VarO-surface reactive antibodies were observed with
total IgG to NTS-DBL1a1 (Rho from 0.38 to 0.67, all P
< 0.006) (Figure 5). A similar observation was valuable
for the CM sub-group (Rho = 0.37, P = 0.02). Less
numerous and strong correlations were observed
between VarO-surface reactive antibodies and IgG1 or
IgG3 levels to varO-domains. Antibodies to the VarO-IE
crude extract correlated to none of the antibody level to
the individual varO-domains in the HA and AP groups
(all Rho < 0.06, all P > 0.18).
Temporal evolution of VarO seroreactivity in
asymptomatic P. falciparum carriers
Forty-five out of the 52 children with asymptomatic P.
falciparum infection in December 2006, were bled again
in January 2008 in order to follow the temporal evolu-
tion of their specific antibody response. Among them,
six were parasitaemic for P. falciparum in 2008, with a
low median parasite density (78 ring forms per microli-
ter of blood, IQ25-75 = 36-158), i.e. were asymptomatic
parasite carriers. The prevalence rate of VarO-IE surface
IgG was lower in 2008 than in 2006 but not that of
VarO-IE crude extract IgG (additional file 1). A similar
decrease between 2006 and 2008 was observed for the
prevalence rates of total IgG, IgG1 and IgG3 to the
three recombinant proteins, except for IgG1 to NTS-
DBL1a1 as well as total IgG and IgG1 to CIDRg, which
remained unchanged (additional file 1). Levels of antibo-
dies to the VarO-IE crude extract dropped in 2008 (P =
0.0007) whereas antibodies reacting with the other anti-
gens remained stable (additional file 1).
Multivariate analysis confirmed the negative effect of
time, consistent with a diminution between 2006 and
Table 2 Median values of antibody responses to varO-IE crude extract and varO recombinant domains, for healthy
adults (HA) and children (AP, UM and SM, in 2006)
Antigens Median values (AU) a
HA (n = 30) AP (n = 52) UM (n = 37) SM (n = 65)
varO-IE
crude extract IgG
95.6 (90.2-97.1) 86.6 (78.4-93.5) b 86.4 (69.7-90.1) c 72.2 (61.1-84.2)
d, f, g
NTS-DBL1a1 :
IgG 93.7 (88.9-99.5) 92.3 (74.0-105.9) 65.7 (61.9-79.9) c, e 64.4 (52.5-83.8) d, f
IgG1 nd 93.3 (82.2-99.3) 34.7 (21.6-50.1) e 37.0 (29.9-60.3) f
IgG3 nd 64.3 (42.9-80.2) 35.7 (27.4-46.8) e 46.3 (36.3-64.6) f, g
CIDRg:
IgG 88.9 (63.6-103.4) 64.2 (49.7-100.9) 74.4 (53.3-107.3) 47.2 (39.3-52.4) d, f
IgG1 nd 83.5 (65.9-97.4) 75.1 (55.4-95.7) 65.1 (51.2-68.9) f
IgG3 nd 65.7 (51.4-81.0) 94.0 (64.2-107.0) 63.9 (45.7-70.0)
DL2bC2:
IgG 73.2 (59.4-90.4) 68.7 (47.0-82.2) 54.8 (43.4-70.8) 47.8 (37.6-68.3) d
IgG1 nd 93.3 (78.8-101.0) 82.8 (75.6-93.0) 81.9 (76.9-93.2)
IgG3 nd 64.2 (47.6-77.0) 48.2 (44.0-53.8) 69.8 (50.7-88.6)
nd: not done
a Median values (25th-75th percentiles), including responders only, and expressed in arbitrary units (AU).
Significant differences (Mann-Whitney U-test, P < 0.05) between median values of HA and AP responders (b), HA and UM responders (c), HA and SM responders
(d), AP and UM responders (e), AP and SM responders (f), and UM and SM responders (g).
Table 3 Correlations between IgG, IgG1 and IgG3 levels
to varO recombinant domains, in children from AP, UM
and SM groups (in 2006)
Correlations NTS-DBL1a1 CIDRg DL2bC2
IgG vs. IgG1:
AP (n = 52) 0.64; P < 0.0001 a 0.87; P < 0.0001 0.79; P < 0.0001
UM (n = 37) 0.42; P = 0.01 0.72; P < 0.0001 0.81; P < 0.0001
SM (n = 65) 0.68; P < 0.0001 0.49; P < 0.0001 0.83; P < 0.0001
IgG vs. IgG3:
AP 0.45; P = 0.0008 0.45; P = 0.0008 0.42; P = 0.002
UM 0.39; P = 0.02 0.49; P = 0.002 0.72; P < 0.0001
SM 0.55; P < 0.0001 0.38; P = 0.002 0.64; P < 0.0001
IgG1 vs. IgG3:
AP 0.44; P = 0.0009 0.44; P = 0.001 0.56; P < 0.0001
UM 0.59; P = 0.0001 0.48; P = 0.003 0.71; P < 0.0001
SM 0.44; P = 0.0002 0.44; P = 0.0002 0.57; P < 0.0001
a Spearman’s rank correlation test (Rho; P)
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2008 of VarO-IE crude extract antibodies (-18.0, P <
0.0001) independently of a positive effect of age (3.4,
P = 0.04) reflecting the ongoing acquisition if immunity.
A similar observation was made for IgG1 to NTS-
DBL1a1 with a negative effect of time (-10.0, P = 0.04)
dominating the positive effect of age (4.2, P = 0.03).
Discussion
Although rosetting is the best-documented cytoadher-
ence phenotype associated with severe malaria in Afri-
can children, little is known on the response acquired to
rosetting parasites in endemic areas. The present study
in Benin confirms the elevated seroprevalence of VarO
in semi-immune children and immune adults observed
in a Senegalese population [31]. Children with severe or
uncomplicated malaria had a much lower anti-varO
response than semi-immune asymptomatic children,
consistent with the conclusion that these antibodies are
associated with protection against clinical malaria in the
age group that progressively mounts a protective
response.
A very high prevalence of the antibodies reacting with
the VarO-IE surface was observed in AP children. The
mean age of the AP children was 6.5 ± 1.3 y, an age at
which children living under such transmission condi-
tions are semi-immune but are still at risk in developing
clinical malaria. As such, and with the caveats of com-
parisons between different studies, the seroprevalence to
VarO-IE in AP children from Ouidah seems higher than
the response to other parasite lines, including the
rosette-forming FCR3S1.2 parasites [41] or a single var-
iant A4var line observed in semi-immune Kenyan chil-
dren living under similar transmission conditions [20],
or to the response to local isolates reported in Tanza-
nian children living in low and moderate transmission
conditions [25]. It is also higher than the response
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observed against a panel of local isolates in Ghanaian
children living in more intense transmission conditions
who had supposedly acquired earlier in life an expanded
antibody repertoire [21]. While these data require
further confirmation, they are consistent with VarO
being a so-called “frequent” or “prevalent” serotype
[42,43] usually associated with severe malaria, which
seems to be a feature of group A var genes [23,44-47]
to which the varO gene belongs. It is not known at pre-
sent whether the reaction observed with the VarO-IE
surface and/or the various -varO-derived recombinant
domains is strictly varO-specific or reflects a broad
cross-reactivity to other “rosetting variants” some of
which also belong to group A var genes [46,48].
Prevalence rates and levels in all VarO-related assays
(IE surface, total IgG, IgG1 and IgG3 to the three
recombinant domains) were much lower in the children
with clinical malaria than in AP children. This difference
remained significant in the multivariate analysis, i.e.
after correcting for age and parasite density at enrol-
ment. It may be possible that the different exposure of
children partly contribute to these findings. However,
AP children were recruited in an area where transmis-
sion intensity was estimated to be lower than in the
Cotonou area where symptomatic children recruited at
hospital lived, although transmission in Cotonou is quite
heterogeneous. Be that as it may, this difference would
translate into a delayed acquisition of antibodies in Oui-
dah compared to Cotonou, as higher transmission inten-
sity is clearly associated with a more rapid acquisition of
an expanded antibody repertoire [23-25]. To further
document the association of VarO-reacting antibodies
with protection against clinical malaria, a longitudinal
follow-up of children is needed to show that the pre-
sence of such antibodies prevents disease caused by
P. falciparum parasites expressing this serotype or
cross-reacting serotypes.
Of the three recombinant domains studied here, NTS-
DBL1a1 had the highest seroprevalence and the highest
antibody levels. In view of the known mosaic structure
of the var genes, this probably indicates that parasites
expressing the varO-NTS-DBL1a1 domain or a related
cross-reacting domain may not co-express varO-CIDRg-
like or varO-DBL2bC2-like domains. Each domain elicits
antibody in the context of where it is presented, i.e., not
necessarily associated with the same domains as those
in the varO gene. This might account for the limited
correlation of the response against the individual
domains in the children with clinical malaria. Although
it is tempting to speculate that the higher seroreactivity
to varO-NTS-DBL1a1 may reflect the generally high
conservation of DBL1a1 sequences across the var reper-
toire and between isolates compared to CIDRg, for
example, which are quite diverse, further study is
needed to test this hypothesis. Furthermore, comparison
of reactivity between different antigens must be inter-
preted with caution because detection depends on the
sensitivity of the assay, which may vary from one to the
other, and because it is difficult to compare arbitrary
units. Notwithstanding these reservations, the observa-
tion of a higher response to NTS-DBL1a1 is consistent
with recent reports on the related R29-DBL1a1 [49] and
the responses to individual domains of the A4var gene
[20], although this was not observed in serological sur-
veys using an array of domains from a number of var
genes [23,24].
VarO-IE surface reactivity correlated best with the
anti-NTS-DBL1a1 IgG, and less strongly with the other
domains. The recombinant NTS-DBL1a1 domain med-
iates rosetting, but a very small percentage of adults
from Benin disrupted more than 50% of the VarO
rosettes, differing in this regard from immune Senega-
lese adults who consistently displayed high VarO
rosettes disrupting capacity [31]. None of the children
sera disrupted VarO rosettes, including sera from AP
children. This confirms previous observations with
Senegalese asymptomatic children of the same age
range, although most had VarO-IE surface-reactive anti-
bodies [31]. The disconnection of rosette-disrupting
antibodies with surface-reacting antibodies observed
here in Benin has been reported in studies conducted in
Kenya and Gabon with other rosette-forming parasites
[50]. This suggests that if recognition of the IE-surface
participates in protection against clinical malaria like
anti-PfEMP1var2csa antibodies against placental malaria
[8,16], other mechanisms than prevention/reversion of
cytoadherence are brought about against rosette-forming
parasites, including possibly complement-mediated lysis
or phagocytosis of the IE. In the Saimiri sciureus mon-
key model, cytophilic antibodies targeting the IE surface
and promoting IE phagocytosis of Palo Alto varO para-
sites were associated with protection against experimen-
tal blood stage challenge and protect animals when
passively administered [33,34]. In this context, it is
interesting to note that indeed a significant IgG1 and
IgG3 response to each of the three recombinant varO
domains could be documented in the Beninese children.
It is thus possible that cytophilic antibodies to the IE
surface contribute to parasite clearance in individuals
that have not (yet) acquired rosette-disrupting antibo-
dies. Both likely contribute to protection, but their
acquisition may be sequential and/or depend on ende-
micity and transmission intensity.
SM and UM children presented similar responses in
all serological assays used here. No changes in the con-
clusions of the analysis were brought when considering
the sub-group of CM children. Based on previous stu-
dies in Gambian [32] or Gabonese children [51] such a
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difference might have been anticipated. The intensity of
surface reaction with VarO-IE tended to be lower in the
SM than in UM Beninese children studied here, but this
difference did not reach significance. The high parasite
density in SM children may be associated with capture
of antibodies onto the parasite antigens and could
account for the observed lack of differences between
SM and UM children. Because of the small volume of
plasma available, the isotype of surface reacting antibo-
dies and the IgG2 and IgG4 antibodies to the recombi-
nant domains were not measured. Therefore, the
possibility exist that SM and UM children differ with
regard of these isotypes. IgG3 antibodies to surface var-
iant antigens have been reported [52], although other
isotypes are produced as well [53]. In one study, IgG4
responses were reported as contributing to protection
[54]. Further studies are needed to clarify this issue and
evaluate the respective role of anti-surface, anti-rosetting
and antibody isotype in the anti-varO response and their
potential contribution to protection against severe or
uncomplicated malaria.
In asymptomatic carriers, the frequency of some anti-
body responses decreased between 2006 and 2008, while
anti-NTS-DBL1a1 IgG1 and anti-CIDRg IgG did not.
The level of antibodies to the recombinant antigens did
not drop. This might reflect the short-lived response
and/or the need of sustained asymptomatic infection
documented in other settings [52,55]. The children iden-
tified as P. falciparum asymptomatic carriers in 2006,
were parasite-free when recruited in January 2008,
except for six children. It is unknown whether these
parasite-free children had been and for how long,
asymptomatic carriers during the 13 months elapsed
between the blood samplings. The 2006-2008 period
matched precisely with a large-scale distribution of long
lasting insecticidal nets [56] to vulnerable populations
(pregnant women and children under 5 years old) in
most towns and villages in the south of Benin. This scal-
ing-up of control measures has very likely reduced
transmission - a sign of this impact might be the very
low rate of asymptomatic infections in the children
recruited in 2008. A reduced circulation of P. falci-
parum parasites in the field, including VarO or VarO-
related parasites, resulting in reducing asymptomatic
carriage and its consequences on maintenance of
immune responses during this period is therefore
plausible.
Conclusions
This study confirms the elevated seroprevalence of VarO
in semi-immune children and immune adults previously
observed in a Senegalese population [31]. It provides
evidence for the production of cytophilic antibodies to
individual PfEMP1 domains. Surface reacting antibodies
correlated with presence of antibodies reacting with the
N-terminal NTS-DBL1a1 domain, consistent with the
stronger response detected to NTS-DBL1a1 compared
to the other domains. The observation of much lower
anti-varO responses in children with clinical malaria
compared to semi-immune asymptomatic children is
consistent with an association of anti-VarO antibodies
with protection against clinical malaria. Interestingly
semi-immune children did not have detectable levels of
antibodies capable of disrupting varO rosettes. This
raises the intriguing possibility that cytophilic antibodies
contribute to protection against clinical malaria by pro-
moting opsonization of the IE, thereby reducing overall
the parasite load.
Additional material
Additional file 1: Comparison between 2006 and 2008 of
prevalence rates and median values of surface-reactive, varO-IE
extract-reactive and recombinant domain-reactive antibodies,
among 45 children classified as asymptomatic (AP) in 2006. a
Median values (interquartile range IQ25-75), including responders only, and
expressed in arbitrary units (AU). b P value of the paired χ2 test. c P value of
the Mann-Whitney U-test, applied to values of responders.
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